Alkermes plc Reports First Quarter 2025 Financial Results
- LYBALVI revenues grew 23% YoY to $70.0M with 22% prescription growth
- Strong cash position of $916.2M, up from $824.8M in December 2024
- Completed enrollment in Vibrance-1 phase 2 study for ALKS 2680
- Maintained profitability with $22.5M GAAP net income
- Total revenues declined from $350.4M in Q1 2024 to $306.5M in Q1 2025
- ARISTADA revenues decreased to $73.5M from $78.9M YoY
- Net income decreased from $38.9M in Q1 2024 to $22.5M in Q1 2025
Insights
Alkermes delivered solid Q1 with declining revenue but maintained profitability. LYBALVI growth offset ARISTADA decline; reaffirmed 2025 guidance.
Alkermes reported Q1 2025 revenues of
The revenue composition shows interesting dynamics across their proprietary portfolio. Total proprietary net sales actually increased by
The overall revenue decline stems primarily from manufacturing and royalty revenues, which dropped substantially from
On the expense side, Alkermes has maintained relatively stable R&D spending at
The balance sheet remains robust with
Beyond financials, Alkermes highlighted significant progress in their pipeline, particularly with ALKS 2680, their orexin 2 receptor agonist for sleep disorders. The company completed enrollment in its first Phase 2 study (Vibrance-1) in narcolepsy type 1, with topline results expected early Q3. Two additional Phase 2 studies are advancing, with the company preparing for Phase 3 development, signaling confidence in this potential breakthrough therapy for disorders of hypersomnolence.
— First Quarter Revenues of
— GAAP Net Income of
— Company Reiterates 2025 Financial Expectations —
"Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achieved an important milestone in the program for ALKS 2680, our novel, investigational, oral orexin 2 receptor agonist, completing enrollment in our first phase 2 study in the program, Vibrance-1, in narcolepsy type 1. We now expect topline results from Vibrance-1 early in the third quarter. We expect to complete enrollment in the Vibrance-2 phase 2 study, in narcolepsy type 2, mid-year, with topline data from that study expected in the fall. Enrollment in Vibrance-3, our phase 2 study in idiopathic hypersomnia, is now also underway. Across the ALKS 2680 development program, we have strong momentum and are preparing for the phase 3 program. With the potential to transform the treatment of central disorders of hypersomnolence, orexin 2 receptor agonists are one of the most exciting new therapeutic categories in development."
Key Financial Highlights
Revenues | ||||
(In millions) | Three Months Ended | |||
2025 | 2024 | |||
Total Revenues | $ | 306.5 | $ | 350.4 |
Total Proprietary Net Sales | $ | 244.5 | $ | 233.5 |
VIVITROL® | $ | 101.0 | $ | 97.7 |
ARISTADA®i | $ | 73.5 | $ | 78.9 |
LYBALVI® | $ | 70.0 | $ | 57.0 |
Profitability | ||||
(In millions) | Three Months Ended | |||
2025 | 2024 | |||
GAAP Net Income From Continuing Operations | $ | 22.5 | $ | 38.9 |
GAAP Net Income (Loss) From Discontinued Operations | $ | -- | $ | (2.1) |
GAAP Net Income | $ | 22.5 | $ | 36.8 |
EBITDA From Continuing Operations | $ | 22.8 | $ | 51.5 |
EBITDA From Discontinued Operations | $ | -- | $ | (2.5) |
EBITDA | $ | 22.8 | $ | 49.0 |
Adjusted EBITDA | $ | 45.6 | $ | 81.8 |
Revenue Highlights
LYBALVI
- Revenues for the quarter were
$70.0 million - Revenues and total prescriptions for the quarter grew
23% and22% , respectively, compared to the first quarter of 2024.
ARISTADAi
- Revenues for the quarter were
$73.5 million
VIVITROL
- Revenues for the quarter were
$101.0 million
Manufacturing & Royalty Revenues
- VUMERITY® manufacturing and royalty revenues for the quarter were
$27.8 million - Royalty revenues from XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® for the quarter were
$17.7 million
Key Operating Expenses
Please see Note 1 below for details regarding discontinued operations.
(In millions) | Three Months Ended | ||||||||||||
2025 | 2024 | ||||||||||||
R&D Expense – Continuing Operations | $ | 71.8 | $ | 67.6 | |||||||||
R&D Expense – Discontinued Operations | $ | -- | $ | 2.5 | |||||||||
SG&A Expense – Continuing Operations | $ | 171.7 | $ | 179.7 | |||||||||
SG&A Expense – Discontinued Operations | $ | -- | $ | -- | |||||||||
Balance Sheet
- At March 31, 2025, the company recorded cash, cash equivalents and total investments of
$916.2 million $824.8 million
Financial Expectations for 2025
Alkermes reiterates its financial expectations for 2025, as set forth in its press release dated Feb. 12, 2025.
Notes and Explanations
1. The company determined that upon the separation of its former oncology business, completed on Nov. 15, 2023, the oncology business met the criteria for discontinued operations in accordance with Financial Accounting Standards Board Accounting Standards Codification 205, Discontinued Operations. Accordingly, the accompanying selected financial information has been updated to present the results of the oncology business as discontinued operations for the three months ended March 31, 2024.
Conference Call
Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense in addition to the components of EBITDA from earnings.
The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA and Adjusted EBITDA should not be considered measures of the company's liquidity.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects, including expected value drivers; and the company's expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, ALKS 2680. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the company is able to achieve its financial expectations; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the
VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI®, INVEGA HAFYERA®, INVEGA TRINZA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license.
________________________________ |
i The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise. |
Alkermes plc and Subsidiaries | ||||
Selected Financial Information (Unaudited) | ||||
Condensed Consolidated Statements of Operations - GAAP | Three Months Ended | Three Months Ended | ||
(In thousands, except per share data) | March 31, 2025 | March 31, 2024 | ||
Revenues: | ||||
Product sales, net | $ 244,493 | $ 233,536 | ||
Manufacturing and royalty revenues | 62,017 | 116,833 | ||
Research and development revenue | — | 3 | ||
Total Revenues | 306,510 | 350,372 | ||
Expenses: | ||||
Cost of goods manufactured and sold | 49,197 | 58,644 | ||
Research and development | 71,817 | 67,611 | ||
Selling, general and administrative | 171,704 | 179,749 | ||
Amortization of acquired intangible assets | — | 1,059 | ||
Total Expenses | 292,718 | 307,063 | ||
Operating Income | 13,792 | 43,309 | ||
Other Income, net: | ||||
Interest income | 10,141 | 9,399 | ||
Interest expense | — | (5,978) | ||
Other income, net | 1,556 | 182 | ||
Total Other Income, net | 11,697 | 3,603 | ||
Income Before Income Taxes | 25,489 | 46,912 | ||
Income Tax Provision | 3,025 | 7,964 | ||
Net Income From Continuing Operations | 22,464 | 38,948 | ||
Loss from Discontinued Operations — Net of Tax | — | (2,120) | ||
Net Income — GAAP | $ 22,464 | $ 36,828 | ||
GAAP Earnings (Loss) Per Share - Basic: | ||||
From continuing operations | $ 0.14 | $ 0.23 | ||
From discontinued operations | — | (0.01) | ||
Earnings per share | $ 0.14 | $ 0.22 | ||
GAAP Earnings (Loss) Per Share - Diluted: | ||||
From continuing operations | $ 0.13 | $ 0.23 | ||
From discontinued operations | — | (0.01) | ||
Earnings per share | $ 0.13 | $ 0.21 | ||
Weighted Average Number of Ordinary Shares Outstanding: | ||||
Basic — GAAP | 163,407 | 167,984 | ||
Diluted — GAAP | 168,737 | 172,981 | ||
Condensed Consolidated Statements of Operations - GAAP (Continued) | Three Months Ended | Three Months Ended | ||
(In thousands, except per share data) | March 31, 2025 | March 31, 2024 | ||
An itemized reconciliation between net income from continuing operations on a GAAP basis and Adjusted EBITDA is as follows: | ||||
Net Income from Continuing Operations | $ 22,464 | $ 38,948 | ||
Adjustments: | ||||
Depreciation and amortization expense | 7,421 | 8,056 | ||
Interest income | (10,141) | (9,399) | ||
Interest expense | — | 5,978 | ||
Income tax provision | 3,025 | 7,964 | ||
EBITDA from Continuing Operations | 22,769 | 51,547 | ||
EBITDA from Discontinued Operations | — | (2,516) | ||
EBITDA | 22,769 | 49,031 | ||
Share-based compensation | 22,810 | 32,755 | ||
Adjusted EBITDA | $ 45,579 | $ 81,786 | ||
Alkermes plc and Subsidiaries | ||||
Selected Financial Information (Unaudited) | ||||
Condensed Consolidated Balance Sheets | March 31, | December 31, | ||
(In thousands) | 2025 | 2024 | ||
Cash, cash equivalents and total investments | $ 916,206 | $ 824,816 | ||
Receivables | 318,703 | 389,733 | ||
Inventory | 183,438 | 182,887 | ||
Contract assets | 3,049 | 4,990 | ||
Prepaid expenses and other current assets | 89,843 | 86,077 | ||
Property, plant and equipment, net | 233,920 | 227,564 | ||
Intangible assets, net and goodwill | 83,899 | 83,917 | ||
Deferred tax assets | 152,144 | 154,835 | ||
Other assets | 100,775 | 100,748 | ||
Total Assets | $ 2,081,977 | $ 2,055,567 | ||
Accrued sales discounts, allowances and reserves | $ 249,795 | $ 272,452 | ||
Other current liabilities | 193,935 | 192,747 | ||
Other long-term liabilities | 126,664 | 125,391 | ||
Total shareholders' equity | 1,511,583 | 1,464,977 | ||
Total Liabilities and Shareholders' Equity | $ 2,081,977 | $ 2,055,567 | ||
Ordinary shares outstanding (in thousands) | 164,853 | 162,177 | ||
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in | ||||
Alkermes Contacts: | ||
For Investors: | Sandy Coombs | +1 781 609 6377 |
For Media: | Katie Joyce | +1 781 249 8927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-plc-reports-first-quarter-2025-financial-results-302443339.html
SOURCE Alkermes plc
FAQ
What were Alkermes (ALKS) key financial results for Q1 2025?
How did LYBALVI perform for Alkermes in Q1 2025?
What is the latest update on Alkermes' ALKS 2680 clinical trials?
How much cash does Alkermes (ALKS) have as of Q1 2025?
